CONCORDIA RX Trademark

Trademark Overview


On Tuesday, August 16, 2016, a trademark application was filed for CONCORDIA RX with the United States Patent and Trademark Office. The USPTO has given the CONCORDIA RX trademark a serial number of 87140304. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, December 6, 2024. This trademark is owned by Concordia Pharmaceuticals Inc., S.à.r.L. The CONCORDIA RX trademark is filed in the Pharmaceutical Products and Medical Instrument Products categories with the following description:

a full line of pharmaceuticals for the treatment of depression, hypertension, malaria, metastatic prostate cancer, benign prostatic hyperplasia, partial seizures in adults with epilepsy, attention deficit hyperactivity disorder (ADHD), heart failure in adults, heart failure in pediatric patients, atrial fibrillation in adults, edema associated with congestive heart failure, edema associated with cirrhosis of the liver, edema associated with nephrotic syndrome, steroid-induced edema, idiopathic edema, edema due to secondary hyperaldosteronism, irritable bowel syndrome (irritable colon, spastic colon, mucous colitis), acute enterocolitis, and duodenal ulcer; anti-inflammatory medicines and immunosuppressive agents (corticosteroids)

Surgical apparatus and instruments for use in surgery; medical apparatus and instruments for use in treating medical conditions, namely, cancer and symptoms related to cancer

General Information


Serial Number87140304
Word MarkCONCORDIA RX
Filing DateTuesday, August 16, 2016
Status710 - CANCELLED - SECTION 8
Status DateFriday, December 6, 2024
Registration Number5472525
Registration DateTuesday, May 22, 2018
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, March 6, 2018

Trademark Statements


Description of MarkThe mark consists of a coin bearing the image of a Roman goddess next to the words "CONCORDIA RX", wherein both terms share a common "R" and the "X" is formed by the rightmost leg of the "R" and a diagonal line crossing it.
Goods and Servicesa full line of pharmaceuticals for the treatment of depression, hypertension, malaria, metastatic prostate cancer, benign prostatic hyperplasia, partial seizures in adults with epilepsy, attention deficit hyperactivity disorder (ADHD), heart failure in adults, heart failure in pediatric patients, atrial fibrillation in adults, edema associated with congestive heart failure, edema associated with cirrhosis of the liver, edema associated with nephrotic syndrome, steroid-induced edema, idiopathic edema, edema due to secondary hyperaldosteronism, irritable bowel syndrome (irritable colon, spastic colon, mucous colitis), acute enterocolitis, and duodenal ulcer; anti-inflammatory medicines and immunosuppressive agents (corticosteroids)
Indication of Colors claimedColor is not claimed as a feature of the mark.
Goods and ServicesSurgical apparatus and instruments for use in surgery; medical apparatus and instruments for use in treating medical conditions, namely, cancer and symptoms related to cancer

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, December 6, 2024
Primary Code005
First Use Anywhere DateTuesday, September 30, 2014
First Use In Commerce DateTuesday, September 30, 2014

International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, December 6, 2024
Primary Code010
First Use Anywhere DateSaturday, November 30, 2013
First Use In Commerce DateSaturday, November 30, 2013

Trademark Owner History


Party NameConcordia Pharmaceuticals Inc., S.à.r.L
Party Type30 - Original Registrant
Legal Entity Type11 - Company
AddressLuxembourg L-1610
LU

Party NameConcordia Pharmaceuticals Inc., S.à.r.L
Party Type20 - Owner at Publication
Legal Entity Type11 - Company
AddressLuxembourg L-1610
LU

Party NameConcordia Pharmaceuticals Inc., S.à.r.L
Party Type10 - Original Applicant
Legal Entity Type11 - Company
AddressLuxembourg L-1610
LU

Trademark Events


Event DateEvent Description
Friday, August 19, 2016NEW APPLICATION ENTERED
Friday, August 19, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, August 20, 2016NOTICE OF DESIGN SEARCH CODE E-MAILED
Monday, November 28, 2016ASSIGNED TO EXAMINER
Tuesday, November 29, 2016NON-FINAL ACTION WRITTEN
Tuesday, November 29, 2016NON-FINAL ACTION E-MAILED
Tuesday, November 29, 2016NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, May 30, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, June 28, 2017ASSIGNED TO LIE
Monday, July 3, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, July 3, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, July 21, 2017NON-FINAL ACTION WRITTEN
Friday, July 21, 2017NON-FINAL ACTION E-MAILED
Friday, July 21, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, January 19, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, January 24, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, January 24, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, January 26, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, February 14, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, March 6, 2018PUBLISHED FOR OPPOSITION
Tuesday, March 6, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 22, 2018REGISTERED-PRINCIPAL REGISTER
Wednesday, September 12, 2018ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Wednesday, June 9, 2021ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Monday, May 22, 2023COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Friday, December 6, 2024CANCELLED SEC. 8 (6-YR)